Provided herein are binding molecules to tumor associated macrophages and associated methods for the treatment and detection of cancer.

An amphiphilic fusion protein has a formula S/I—X—H.sub.1—H.sub.2, wherein S— is a solubilizing moiety, I— is an insolubilizing moiety, —X— is a peptide sequence comprising a proteolytic or chemical cleavage site, —H.sub.1— is a hydrophilic peptide, and —H.sub.2 is a hydrophobic peptide.

Described herein is the finding that increasing the frequency of Zscan4 activation in mouse ES cells not only enhances, but also maintains their developmental potency in long-term cell culture. Particularly disclosed herein is the finding that the constitutive presence of Zscan4-ERT2, even in the absence of its usual activator tamoxifen, can increase the frequency of endogenous Zscan4 activation in ES cells, resulting in the increase of developmental potency of the ES cells. Accordingly, provided herein are Zscan4-ERT2 fusion proteins and nucleic acid molecules and vectors encoding Zscan4-ERT2 fusion proteins. Further provided are methods of prolonging and/or enhancing stem cell plmipotency using the disclosed Zscan4-ERT2 nucleic acid molecules and fusion proteins.

The present invention relates to the technical field of biological preparation, and particularly to a RXRα gene knockout cell line with stable and low RXRα protein expression. The cell line is a RXRα gene knockout cell line, in which non-3 integer multiple of bases are knocked out. The RXRα protein expression in the cells is significantly decreased and the genotype is stable to be passaged, thus greatly improving the stability of the cell line with low RXRα protein expression. This is conducive to the stable passage and continuous culture of the cell line. The present invention further provides a production method of the cell line.

Short peptides and peptidomimetics useful for treating Type 2 diabetes are provided, and methods for treating and/or preventing Type 2 diabetes and related conditions.

Disclosed herein are methods of treating neurodevelopmental disorders such as schizophrenia (SCZ), bipolar disorder or depression. The methods entail inhibiting expression of miR-219 or overexpressing TLX thereby promoting proliferation of neural stem cells (NSCs) in the subjects.

The present invention relates to novel peptides derived from Nuclear receptor subfamily 0 group B member 1 (NR0B1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.

The present invention provides compositions, methods, and kits comprising one or more ROR inhibitors, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, lymphoma, and glioma.

Disclosed herein is an amyloid accumulation and/or aggregation inhibitor. A technique for inhibiting amyloid accumulation and/or aggregation by concurrently introducing Nurr1 and Foxa2 genes and introducing the co-expression of the genes is also provided. When used, the composition can be applied to the prevention or treatment of a neurodegenerative disease caused by amyloid accumulation and/or aggregation, such as Alzheimer's disease.